Wednesday, June 18, 2025 at 2-3pm ET                            Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Join us for a webinar on the Managed Care Approaches to Bispecific Antibodies, focusing on follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Each year, approximately 81,000 individuals in the United States are diagnosed with non-Hodgkin lymphoma (NHL), while 20,000 are expected to face mortality. The two most common sub-types of NHL include aggressive diffuse large B-cell lymphoma (30% of NHL) and indolent follicular lymphoma (22% of NHL). While an indolent disease, follicular lymphoma can transform into aggressive DLBCL, occurring in up to 10% of cases.

Learning Objectives

• Provide an update on the unique science, mechanisms of action, and dosing protocols of bispecific antibodies (BsAbs), emphasizing distinctions from traditional monoclonal antibodies and BiTEs, and their role in treatment sequencing for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
• Review clinical trial results and real-world evidence for BsAbs, focusing on outcomes such as mortality, adverse events, and hospitalizations.
• Examine the cost-effectiveness of BsAbs compared to alternative treatment pathways for FL and DLBCL.
• Explore payer perspectives on the role of BsAbs, including their use in combination therapy, site-of-care considerations, and implications for benefit designs.
• Gain insights into best practices for managed care organizations (MC)s) in managing BsAbs effectively.